Orthotopic tumor model has become an essential tool for studying drug biodistribution and tumor progression over time owing to the rapid development of in vivo imaging and immunological science. Dynamic diffuse fluorescence tomography (DFT) is a promising imaging modality that can map the three-dimensional distribution of a fluorophore within the object and capture the metabolic parameters of fluorophores in vivo. It has been widely applied in tumor detection, drug development, and efficacy evaluation. To detect orthotopic liver tumors, we combined indocyanine green (ICG) and a DFT system to perform fluorescence imaging and quantitative analysis for orthotopic liver tumors in mice. The orthotopic liver models were first established, and the liver fluorescence yields were detected in pre- and post-cancerous liver using the DFT system. The results showed that there was higher liver uptake and prolonged retention in orthotopic tumor liver compared to normal liver. Furthermore, the pharmacokinetic parameters suggested the uptake coefficient of tumor liver was above twice that of normal liver, while the excretion rates were similar. Additionally, to intuitively assess tumor occurrence, we propose using normalized fluorescence ratios of 5 and maximum fluorescence values of 0.01 mm as evaluation criteria. The study demonstrates DFT imaging is a promising tool in orthotopic tumor model detection and drug or agent metabolic evaluation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbio.70003 | DOI Listing |
J Biophotonics
March 2025
College of Precision Instrument and Optoelectronics Engineering, Tianjin University, Tianjin, China.
Orthotopic tumor model has become an essential tool for studying drug biodistribution and tumor progression over time owing to the rapid development of in vivo imaging and immunological science. Dynamic diffuse fluorescence tomography (DFT) is a promising imaging modality that can map the three-dimensional distribution of a fluorophore within the object and capture the metabolic parameters of fluorophores in vivo. It has been widely applied in tumor detection, drug development, and efficacy evaluation.
View Article and Find Full Text PDFGut microbiota and integrins are known to contribute to colorectal cancer (CRC), but whether they interact has been unclear. Here, we provided evidence that upregulated integrin α5 (ITGA5) in CRC in both human patients and murine models. Knocking down in CRC cells weakened the ability of to stimulate their malignant characteristics.
View Article and Find Full Text PDFMed Mol Morphol
March 2025
Department of Biophysics, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-Ku, Kobe, 654-0142, Japan.
Pancreatic cancer is a malignant tumor that metastasizes to distant organs, such as the liver and lungs from an early stage. Few animal models can reproduce early metastasis. In addition, no model has been reported that reproduces cancer-related hypercoagulability, which is characteristic of pancreatic ductal adenocarcinoma and other adenocarcinomas.
View Article and Find Full Text PDFWorld J Gastroenterol
March 2025
National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China.
Background: Shortening the recipient warm ischemia time (rWIT) has been proven to be effective for improving the short- and long-term outcomes after liver transplantation (LT) and offsets the negative impact of an extended cold ischemia time. However, few studies have been conducted to explore the prognostic effects of shortening the rWIT in transplantations using a liver graft from an extended-criteria donor (ECD).
Aim: To investigate whether shortening the rWIT could improve the outcomes of ECD LT.
Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of only 10% in the United States. While immune checkpoint blockade (ICB) has shown efficacy in many solid tumors, PDAC remains largely unresponsive. Agonistic CD40 antibodies can activate PDAC-associated myeloid cells, enhancing innate and adaptive anti-tumor immunity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!